Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteasome subunit alpha type-1 (PSMA1) is an essential component of the 20S proteasome core complex, playing a structural and regulatory role in cellular protein degradation through the ubiquitin-proteasome pathway. As part of the multicatalytic complex, it contributes to forming the alpha-ring gating system that controls substrate entry into the internal proteolytic chamber. The 20S core, together with regulatory particles (such as 19S, 11S), mediates ATP-dependent and independent cleavage of polyubiquitinated, misfolded, or damaged proteins, thus ensuring cellular protein quality control, regulating cell cycle, apoptosis, and immune functions (particularly antigen presentation via MHC class I). PSMA1 has gained interest as a cancer target due to its overexpression and oncogenic roles in several solid tumors and hematologic malignancies, notably mediating cancer cell proliferation, migration, invasion, and resistance to therapy. Drugs targeting the proteasome, like bortezomib and carfilzomib, are used therapeutically in multiple myeloma and other cancers. However, inhibition of proteasome activity is associated with significant side effects and the emergence of therapeutic resistance. Elevated PSMA1 expression is associated with poor prognosis in cancers such as gastric and colon cancer, and its detection can serve as a biomarker for tumor burden.
Inhibition of proteasomal protein degradation; Disruption of ubiquitin-proteasome pathway; Stabilization/accumulation of regulatory proteins (e.g., pro-apoptotic proteins, cell cycle proteins)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome subunit alpha type-1 (PSMA1).